Article
Oncogenic alterations in ERBB2/HER2 represent potential therapeutic targets across tumors from diverse anatomic sites of origin.
The oncologist - 1 Jan 2015
Chmielecki Juliann, Ross Jeffrey S, Wang Kai, Frampton Garrett M, Palmer Gary A, Ali Siraj M, Palma Norma, Morosini Deborah, Miller Vincent A, Yelensky Roman, Lipson Doron, Stephens Philip J
Abstract excerpt
BACKGROUND: Targeted ERBB2/HER2 inhibitors are approved by the U.S. Food and Drug Administration for the treatment of breast, gastric, and esophageal cancers that overexpress or amplify HER2/ERBB2, as measured by immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH), respectively. Activating mutations in ERBB2 have also been reported and are predicted to confer sensitivity to these targeted...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.